Curosurf (Poractant Alfa) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to high incidence of preterm births, proven efficacy in rds treatment, widespread nicu adoption, clinical guidelines supporting surfactant therapy, reduced neonatal mortality rates.

The growth in the forecast period can be attributed to increasing premature birth rates globally, expansion of nicu infrastructure, improved neonatal care access, rising awareness of early rds intervention, continued clinical validation. Major trends in the forecast period include rising use in neonatal intensive care, growing adoption of synthetic surfactants, increasing focus on preterm birth management, standardization of rds treatment protocols, expansion of hospital based neonatal therapies.

The increasing prevalence of respiratory disorders is anticipated to drive the growth of the Curosurf (poractant alfa) market in the coming years. Respiratory disorders include common conditions that affect lung function and breathing, such as asthma, chronic obstructive pulmonary disease (COPD), and lung cancer, often resulting in breathing difficulties and reduced respiratory capacity. The rising incidence of these disorders is largely attributed to increasing air pollution, which worsens conditions like asthma, as well as an aging population that is more susceptible to age-related illnesses such as COPD. Poractant alfa is used in the treatment of neonatal respiratory distress syndrome by enhancing lung function and supporting effective breathing in premature infants through administration via an endotracheal tube. For instance, in December 2023, according to the National Library of Medicine, a US-based medical library, the global number of COPD cases among individuals aged 25 and older is expected to increase by 23% by 2050, reaching nearly 600 million cases. Therefore, the growing prevalence of respiratory disorders is contributing to the expansion of the Curosurf (poractant alfa) market.

The rising prevalence of premature births is expected to further propel the growth of the Curosurf (poractant alfa) market going forward. Premature births refer to infants born before 37 weeks of gestation, whereas a full-term pregnancy generally lasts around 40 weeks. The increase in premature births is associated with factors such as higher maternal age and the growing use of assisted reproductive technologies, which often result in multiple pregnancies. Poractant alfa is administered to premature infants with respiratory distress syndrome to lower lung surface tension, keep the lungs open, and enhance oxygen exchange. For instance, in July 2025, according to the Office for National Statistics, a UK-based government department, England and Wales recorded 594,677 live births in 2024, reflecting an increase of 3,605 births, or 0.6%, compared to the 591,072 births reported in 2023. Consequently, the increasing prevalence of premature births is driving the growth of the Curosurf (poractant alfa) market.

Key companies operating in the Curosurf (poractant alfa) market are emphasizing the development of innovative solutions, including novel inhaled gene therapies, to address unmet needs in the treatment of respiratory disorders. Novel inhaled gene therapy involves an advanced approach in which therapeutic genes are delivered directly to the lungs through inhalation, typically using aerosolized particles or nanoparticles. For example, in November 2024, AlveoGene, a UK-based gene therapy developer, received Rare Pediatric Disease Designation from the FDA for AVG-002, an inhaled gene therapy designed to treat lethal neonatal surfactant protein B (SP-B) deficiency, a rare genetic condition that causes severe respiratory failure in infants. SP-B deficiency, resulting from mutations in the SFTPB gene, currently has limited treatment options and often requires lung transplantation. AVG-002 uses AlveoGene’s InGenuity platform to deliver a functional SP-B gene directly to the lungs and has demonstrated promising outcomes in preclinical studies.

Major companies operating in the curosurf (poractant alfa) market are Chiesi Farmaceutici S.p.A.

North America was the largest region in the curosurf (poractant alfa) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the curosurf (poractant alfa) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the curosurf (poractant alfa) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the curosurf market by increasing the cost of imported pharmaceutical intermediates and sterile manufacturing components used in surfactant production. These cost pressures are most evident in hospital supply chains across Asia Pacific and Latin America, where neonatal care demand is rising rapidly. Distribution and cold chain logistics have also been affected due to duties on medical packaging materials. Neonatal intensive care units face higher procurement costs as a result. At the same time, tariffs are encouraging localized manufacturing partnerships and regional production of neonatal respiratory therapeutics.

The curosurf (poractant alfa) market research report is one of a series of new reports that provides curosurf (poractant alfa) market statistics, including curosurf (poractant alfa) industry global market size, regional shares, competitors with a curosurf (poractant alfa) market share, detailed curosurf (poractant alfa) market segments, market trends and opportunities, and any further data you may need to thrive in the curosurf (poractant alfa) industry. This curosurf (poractant alfa) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Curosurf (poractant alfa) is a synthetic pulmonary surfactant primarily used for the prevention and treatment of respiratory distress syndrome (RDS) in preterm newborns. It represents a synthetic form of pulmonary surfactant, a naturally occurring substance in the lungs that lowers surface tension and helps keep the alveoli (tiny air sacs) from collapsing.

The main types of Curosurf (poractant alfa) include Natural Poractant Alfa and Synthetic Poractant Alfa. Natural poractant alfa is obtained from animal lung extracts, mainly from porcine (pig) sources. It is distributed through multiple sales channels, such as direct sales, distribution networks, and online marketplaces, and is used for various applications including pulmonary edema, respiratory distress syndrome, and other respiratory conditions. The end users of Curosurf include hospitals, clinics, and ambulance services.

The curosurf (poractant alfa) market consists of sales of generic versions of poractant alfa, fostair, flemax, bricanils, and synthetic pulmonary surfactants. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.